Acitretin

Drug Profile

Acitretin

Alternative Names: Acitretine; Etretin; Neotigason; RO 101670; Soriatane

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Allergan; Aralez Pharmaceuticals Inc.; Innovaderm Research; Roche; Stiefel Laboratories; University of Medicine & Dentistry of New Jersey
  • Class Antipsoriatics; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Discontinued Cancer; Dermatitis

Most Recent Events

  • 10 Jul 2017 Discontinued - Phase-II for Psoriasis (Adjunctive treatment) in USA (PO), because not listed on Allergan pipeline, July 2017
  • 10 Jul 2017 Discontinued - Phase-II/III for Dermatitis in Canada (PO), because not listed on Allergan pipeline, July 2017
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top